Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels

Management of castration-resistant prostate cancer (CRPC) is challenging due to lack of efficacious therapy. Luteinizing hormone-releasing hormone (LHRH) analogs appear to act directly on cells based on the LHRH receptors on human prostate adenocarcinoma cells. We explored anticancer activity of a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Popovics, Petra, Schally, Andrew V., Szalontay, Luca, Block, Norman L., Rick, Ferenc G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147346/
https://www.ncbi.nlm.nih.gov/pubmed/24994120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147346/
https://www.ncbi.nlm.nih.gov/pubmed/24994120

Ejemplares similares